Fidelity Investments
NRIX icon

Fidelity Investments’s Nurix Therapeutics NRIX Stock Holding History

Fidelity Investments’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133M Sell
5,485,215
-56,056
-1% -$955K 0.01% 1113
2026
Q1 		$85.9M Buy
5,541,271
+1,307,113
+31% +$21.7M ﹤0.01% 1242
2025
Q4 		$80.3M Sell
4,234,158
-4,653,379
-52% -$66.8M ﹤0.01% 1269
2025
Q3 		$82.1M Sell
8,887,537
-1,554,930
-15% -$16.1M ﹤0.01% 1262
2025
Q2 		$119M Buy
10,442,467
+110,256
+1% +$1.19M 0.01% 1045
2025
Q1 		$123M Sell
10,332,211
-302,020
-3% -$5.05M 0.01% 1005
2024
Q4 		$200M Buy
10,634,231
+10,047,329
+1,712% +$230M 0.01% 824
2024
Q3 		$13.2M Buy
586,902
+511,256
+676% +$11.6M ﹤0.01% 1839
2024
Q2 		$1.58M Buy
75,646
+4,284
+6% +$66.7K ﹤0.01% 2405
2024
Q1 		$1.05M Sell
71,362
-252,367
-78% -$2.71M ﹤0.01% 2488
2023
Q4 		$3.34M Buy
323,729
+2,822
+0.9% +$19.3K ﹤0.01% 2180
2023
Q3 		$2.52M Sell
320,907
-95,706
-23% -$874K ﹤0.01% 2225
2023
Q2 		$4.16M Sell
416,613
-33,631
-7% -$343K ﹤0.01% 2117
2023
Q1 		$4M Sell
450,244
-553,399
-55% -$5.77M ﹤0.01% 2158
2022
Q4 		$11M Sell
1,003,643
-682,008
-40% -$8.23M ﹤0.01% 1846
2022
Q3 		$22M Sell
1,685,651
-105,004
-6% -$1.66M ﹤0.01% 1580
2022
Q2 		$22.7M Buy
1,790,655
+668,632
+60% +$7.58M ﹤0.01% 1601
2022
Q1 		$15.7M Buy
1,122,023
+13,920
+1% +$247K ﹤0.01% 1902
2021
Q4 		$32.1M Buy
1,108,103
+449,486
+68% +$13.6M ﹤0.01% 1600
2021
Q3 		$19.7M Hold
658,617
– – ﹤0.01% 1855
2021
Q2 		$17.5M Buy
658,617
+79,532
+14% +$2.33M ﹤0.01% 1895
2021
Q1 		$18M Buy
579,085
+243,400
+73% +$9.21M ﹤0.01% 1840
2020
Q4 		$11M Hold
335,685
– – ﹤0.01% 1937
2020
Q3 		$11.7M Buy
+335,685
New +$8.46M ﹤0.01% 1773

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments's NRIX Position: Q2 2026 in Review

Fidelity Investments reduced its Nurix Therapeutics (NRIX) stake by 1% in Q2 2026, selling an estimated $955K and leaving 5,485,215 shares worth $133M. The position accounts for 0.01% of the portfolio, ranked #1113.

Fidelity Investments first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $200M in Q4 2024. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Fidelity Investments held 5,485,215 shares of Nurix Therapeutics worth $133M as of Q2 2026.
  • Fidelity Investments sold 56,056 Nurix Therapeutics shares in Q2 2026, an estimated $955K.
  • Nurix Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #1113 holding.
  • Fidelity Investments first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Fidelity Investments's Nurix Therapeutics position peaked at $200M in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.